Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.70 |
| ▸ | JAK3 | P52333 | 6/20 | 0.64 |
| ▸ | FLT3 | P36888 | 3/20 | 0.64 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.64 |
| ▸ | PAK4 | O96013 | 3/20 | 0.64 |
| ▸ | CSF1R | P07333 | 3/20 | 0.64 |
| ▸ | RET | P07949 | 3/20 | 0.64 |
| ▸ | MET | P08581 | 3/20 | 0.64 |
| ▸ | PIM1 | P11309 | 3/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.64 |
| ▸ | PRKACA | P17612 | 3/20 | 0.64 |
| ▸ | FLT1 | P17948 | 3/20 | 0.64 |
| ▸ | LTK | P29376 | 3/20 | 0.64 |
| ▸ | GRK5 | P34947 | 3/20 | 0.64 |
| ▸ | KDR | P35968 | 3/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.64 |
| ▸ | CLK2 | P49760 | 3/20 | 0.64 |
| ▸ | GSK3A | P49840 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13765436 | 0.84 | JAK2 (0.72) | JAK2JAK3FLT3DAPK3PRKD3 | |
| SCHEMBL29291556 | 0.83 | CIT (0.58) | JAK2JAK3FLT3DAPK3PRKD3 | |
| SCHEMBL29291540 | 0.83 | CIT (0.58) | JAK2JAK3FLT3DAPK3PRKD3 | |
| SCHEMBL4582349 | 0.83 | JAK2 (0.70) | JAK2JAK3FLT3DAPK3PRKD3 | |
| SCHEMBL15661177 | 0.83 | JAK2 (0.70) | JAK2JAK3FLT3DAPK3PRKD3 | |
| SCHEMBL27753707 | 0.83 | JAK2 (0.70) | JAK2JAK3FLT3DAPK3PRKD3 | |
| SCHEMBL4006751 | 0.82 | JAK2 (1.00) | JAK2JAK3FLT3DAPK3PRKD3 | |
| SCHEMBL12127462 | 0.82 | JAK2 (0.64) | JAK2JAK3FLT3DAPK3PRKD3 | |
| SCHEMBL15660152 | 0.82 | JAK3 (0.76) | JAK2JAK3FLT3DAPK3PRKD3 | |
| SCHEMBL24804159 | 0.81 | CIT (0.63) | JAK2JAK3FLT3DAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284394-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (US) | 2015-10-08 | — | — | US | claimed |
| WO-2014064131-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-01 | — | — | WO | claimed |
| CN-104662024-B | Tyrosine kinase inhibitors | 弗·哈夫曼-拉罗切有限公司 | 2016-12-07 | — | — | CN | disclosed |
| US-20150284394-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284394-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284394-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (US) | 2015-10-08 | — | — | US | disclosed |
| WO-2014064131-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014064131-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-01 | — | — | WO | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | JAK2 402/4885JAK3 648/4885FLT3 230/4885 |
| US-20150284394-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | JAK2 43/4885JAK3 179/4885FLT3 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.